Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 7/20 | 0.33 |
| ▸ | CDK1 | P06493 | 6/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.33 |
| ▸ | CDK2 | P24941 | 6/20 | 0.33 |
| ▸ | CCND1 | P24385 | 6/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.33 |
| ▸ | CCND3 | P30281 | 3/20 | 0.33 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.33 |
| ▸ | IKBKB | O14920 | 6/20 | 0.33 |
| ▸ | CHUK | O15111 | 6/20 | 0.33 |
| ▸ | IKBKG | Q9Y6K9 | 6/20 | 0.33 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13638291 | 0.91 | CDK4 (0.36) | CDK4CDK1CCNA2CDK2CCND1 | |
| SCHEMBL13638429 | 0.88 | IKBKB (0.34) | CDK4CDK1CCNA2CDK2CCND1 | |
| SCHEMBL13638303 | 0.88 | IKBKB (0.43) | CDK4CDK1CCNA2CDK2CCND1 | |
| SCHEMBL13638292 | 0.87 | KDR (0.37) | CDK4CDK1CCNA2CDK2CCND1 | |
| SCHEMBL13638579 | 0.87 | SRC (0.35) | CDK4CDK1CCNA2CDK2CCND1 | |
| SCHEMBL4478692 | 0.87 | KCNH2 (0.35) | CDK4CDK1CCNA2CDK2CCND1 | |
| SCHEMBL13638557 | 0.86 | IKBKB (0.45) | CDK4CDK1CCNA2CDK2CCND1 | |
| SCHEMBL13638577 | 0.86 | AKT3 (0.36) | CDK4CDK1CCNA2CDK2CCND1 | |
| SCHEMBL13638578 | 0.85 | IKBKB (0.37) | CDK4CDK1CCNA2CDK2CCND1 | |
| SCHEMBL13638306 | 0.85 | IKBKB (0.34) | CDK4CDK1CCNA2CDK2CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | CDK4 681/4885CDK1 555/4885CCNA2 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.